中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 4
Apr.  2011

Serum thymosin β4 level in patients with hepatocellular carcinoma

Research funding:

 

  • Published Date: 2011-04-20
  • Objective To investigate serum thymosin β4 (Tβ4) level in patients with hepatocellular carcinoma (HCC) .Methods Serum Tβ4 level were measured in 80 patients with HCC, 40 patients with cirrhosis and 40 healthy controls.Serum Tβ4 level were measured by enzyme-linked immunosorbent assay (ELISA) .Level of serum Tβ4 in different stages of HCC were compared.Patients with HCC were divided into groups according with or without interhepatic metastasis, portal vein tumor thrombus and distant metastasis and then compared.Results Compared with that in healthy controls, serum Tβ4 level in patients with HCC and cirrhosis was lower with statistically significant difference (χ2=81.228, P<0.001) .Patients with HCC had divided into group A, B, C and D according their BCLC stage.Level of Tβ4 in these 4 groups was statistically significant difference (χ2=8.669, P=0.034) .Patients with HCC were divided into group 0, 1, 2, 3, 4 and 5 according CLIP score.Level of Tβ4 in these 6 groups had statistically significant difference (χ2=13.675, P=0.018) .Meanwhile, Patients with HCC were also divided according interhepatic metastasis, portal vein tumor thrombus and distant metastasis.Serum Tβ4 level was higher in patients with interhepatic metastasis than that in those without metastasis (Z=2.264, P=0.024) .Serum Tβ4 level was higher in patients with portal vein tumor thrombus than that in those without tumor thrombus (Z=2.574, P=0.010) .Patients who developed neither portal vein tumor thrombus nor distant metastasis were divided into group A, B and C according Child-pugh grade and there was statistically significant difference (χ2=6.467, P=0.039) .Conclusion Serum Tβ4 level in patients with HCC were lower than that in healthy controls.And serum Tβ4 level in patients with interhepatic metastasis or portal vein tumor thrombus was higher than that in patients without those diseases.

     

  • [1]Low TL, Goldstein AL.Chemical characterization of thymosinbeta 4[J].J Biol Chem, 1982, 257 (2) :1000-1006.
    [2]Xu GJ, Hannappel E.Determination of thymosin beta 4 byperitoneal macrophages and adherent spleen cells[J].ProcNatl Acad Sci, 1982, 79 (13) :4006-4009.
    [3]Han T, Liu Y, Liu H, et al.Serum thymosinβ4 level inpatient with hepatitis B virus-related liver failure[J].World JGastroenterol, 2010, 16 (5) :625-630.
    [4]Bruix J, Sherman M.Management of hepatocellularcarcinoma[J].Hepatology, 2005, 42 (5) :1208-1236.
    [5]Llovet JM, Bru C, Bruix J.Prognosis of hepatocellularcarcinoma:the BCLC staging classification[J].Semin LiverDis, 1999, 19 (3) :329-338.
    [6]Llovet JM, Burroughs A, Bruix J.Hepatocellular carcinoma[J].Lancet, 2003, 362 (9399) :1907-1917.
    [7]The Cancer of the Liver Italian Program (CLIP) investigators.Prospective validation of the CLIP score:a new prognosticsystem for patients with cirrhosis and hepatocellularcarcinoma[J].Hepatology, 2000, 31 (4) :840-845.
    [8]Carlier MF, Didry D, Erk I, et al.Tbeta 4 is not a simple G-actinsequestering protein and interacts with F-actin at highconcentration[J].J Biol Chem, 1996, 271 (16) :9231-9239.
    [9]Philp D, Badamchian M, Scheremeta B, et al.Thymosin beta 4and a synthetic peptide containing its actin-binding domainpromote dermal wound repaire in db/db diabetic mice and inaged mice[J].Wound Repair Regen, 2003, 11 (1) :19-24.
    [10]Bock-Marqutte I, Saxena A, White MD, et al.Thymosin beta4 activates integrin-linked kinase and promotes cardiaccell migration, survival and cardiac repair[J].Nature, 2004, 432 (7016) :466-472.
    [11]Sosne G, Qiu P, Christopherson PL, et al.Thymosin beta4suppression of corneal NFκB:a potential anti-inflammatorypathway[J].Exp Eye Res, 2007, 84 (4) :663-669.
    [12]Cha HJ, Jeong MJ, Kleinman HK.Role of thymosinβ4 intumor metastasis and angiogenesis[J].J Natl Cancer Inst, 2003, 95 (22) :1674-1680.
    [13]Mai I, Kazuhiro I, Shigeyuki U, et al.Overexpression of thymosinβ4 increases pseudopodia formation in LNCaP prostatecancer cells[J].Biol Pharm Bull, 2009, 32 (6) :1101-1104.
    [14]Wang WS, Chen PM, Hsiao HL, et al.Overexpression ofthe thymosin beta 4 gene is associated with malignantprogression of SW480 colon cancer cells[J].Oncogene, 2003, 22 (21) :3297-3306.
    [15]Barnaeva E, Nadezhda A, Hannappel E, et al.Thymosin beta4upregulates the expression of hepatocyte growth factor anddownregulate the expression of PDGF-beta receptor in humanhepatic stellate cells[J].Ann N Y Acad Sci, 2007, 1112:154-160.
    [16]Hsiao HL, Wang WS, Chen PM, et al.Overexpression of thymosinbeta-4 renders SW480 colon carcinoma cells more resistant toapoptosis triggered by FasL and two topoisomeraseⅡinhibitorsvia downregulating Fas and upregulating Survivin expression, respectively[J].Carcinogenesis, 2006, 27 (5) :936-944.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (4204) PDF downloads(896) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return